PhaseBio Pharmaceuticals Inc
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|
| Revenue | $10.8M | $320,000 | $2.4M | $668,000 | — |
| Operating income | −$107.4M | −$84.9M | −$39.7M | −$19.6M | −$8.5M |
| Net income | −$131.1M | −$98.6M | −$39.2M | −$23.8M | −$10.2M |
| Total assets | $60.5M | $50.4M | $82.5M | $63.0M | $14.1M |
| Total liabilities | $153.6M | $75.6M | $22.5M | $12.1M | $21.9M |
| Equity | −$93.0M | −$25.2M | $60.0M | $50.9M | −$97.4M |
| EPS (diluted) | $-2.98 | $-3.39 | — | — | — |
| Shares out. | 29.4M | 28.8M | 24.5M | 24.5M | 745,788 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −991.2%
- Net margin
- −1210.1%
- Return on equity
- 140.9%
- Return on assets
- −216.5%
- Return on capital (ROCE)
- −328.8%
- Liabilities / assets
- 253.7%
- Debt / equity
- —
- Book value / share
- $-3.16
- Revenue growth (YoY)
- 3284.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -31.39distress
- Accruals / assets
- −138.2%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 15, 2024
- NT 10-Qmissed a reporting deadline ↗May 16, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
- NT 10-Qmissed a reporting deadline ↗Aug 25, 2023
- NT 10-Qmissed a reporting deadline ↗May 16, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Van Den Broek RichardDirector | May 19, 2023 | Grant | 3,750 | — |
| Thorp ClayDirector | May 19, 2023 | Option exercise | 3,750 | — |
| Humphries William D.Director | May 19, 2023 | Option exercise | 2,538 | — |
| Harrigan EdmundDirector | May 19, 2023 | Option exercise | 3,750 | — |
| Sapir AlexDirector | May 19, 2023 | Option exercise | 3,750 | — |
| Loewy Caroline MDirector | May 19, 2023 | Option exercise | 3,750 | — |
| Hutson Nancy JDirector | May 19, 2023 | Option exercise | 3,750 | — |
| New Enterprise Associates 13 Lp10% owner | Oct 25, 2022 | Sell | 1.8M | $0.15 |
| Arnold Susan ElizabethOfficer — SVP, Technical Operations | May 20, 2022 | Grant | 10,917 | $0.68 |
| Mow Jonathan POfficer — Chief Executive Officer | May 20, 2022 | Grant | 10,918 | $0.68 |
| Burkhardt GlenOfficer — SVP of Human Resources | May 20, 2022 | Grant | 11,248 | $0.68 |
| Hanson KristopherOfficer — SVP and General Counsel | May 20, 2022 | Grant | 4,831 | $0.68 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Other material eventAug 15, 2024
- Bankruptcy or receivership · Other material eventJul 12, 2024
- Other material eventMay 16, 2024
- Entered a material agreement · Other material eventMar 12, 2024
- Other material eventNov 29, 2023
- Director / officer changeOct 3, 2023
- Other material eventSep 27, 2023
- Other material eventAug 25, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.